# MeiraGTx Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meiragtx-holdings

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.meiragtx.com
- Total disclosed funding: $50M
- Latest round: Series B (Jun 1, 2017)
- Investors on record: 1

## About

Based in the US, MeiraGTx Holdings plc specializes in next-generation genetic medicine, employing innovative technologies for precise gene expression control to develop therapies for genetic disorders.MeiraGTx Holdings plc is a biotechnology firm founded in 2015, headquartered in New York, US. The company specializes in genetic therapies and has undertaken five notable deals, with the most recent funding round dated June 7, 2018. On that date, MeiraGTx raised USD 30.00 mn from prominent investors including Sanofi Ventures. Zandy Forbes serves as the CEO, steering the company through its developmental stages in gene therapy.MeiraGTx provides advanced genetic medicine solutions, such as its proprietary riboswitch gene regulation platform, which offers unique control over gene expression. This technology is aimed at treating various inherited diseases, with a focus on improving patient outcomes. Its client base includes healthcare providers and research institutions in North America, Europe, and Asia, who utilize these innovative gene therapy products.In 2023, MeiraGTx reported a revenue of USD 14.02 mn, with an EBITDA of USD -122.07 mn. The company generates revenue primarily through partnerships with biopharmaceutical companies and collaborative agreements with research institutions, utilizing its gene therapy technologies for both clinical and research applications.Looking ahead, MeiraGTx is focused on launching new genetic therapy products designed to target specific conditions in patients, with plans for market introductions in North America and Europe by 2025. The recent funding of USD 30.00 mn is earmarked for expanding its research and development initiatives, enhancing its product offerings, and bolstering its presence in existing and new markets. The company aims to solidify its position in the genetic medicine landscape through strategic collaborations and innovative solutions.

## Funding rounds

- Series B, Jun 1, 2017, $50M — Albion Capital

## Investors

- Albion Capital — Series B